HomeCompareNHIQ vs MRK

NHIQ vs MRK: Dividend Comparison 2026

NHIQ yields 16666.67% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NHIQ wins by $8601297707047409664.00M in total portfolio value
10 years
NHIQ
NHIQ
● Live price
16666.67%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8601297707047409664.00M
Annual income
$8,500,961,637,704,150,000,000,000.00
Full NHIQ calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — NHIQ vs MRK

📍 NHIQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNHIQMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NHIQ + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NHIQ pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NHIQ
Annual income on $10K today (after 15% tax)
$1,416,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,225,817,392,048,527,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, NHIQ beats the other by $7,225,817,392,048,527,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NHIQ + MRK for your $10,000?

NHIQ: 50%MRK: 50%
100% MRK50/50100% NHIQ
Portfolio after 10yr
$4300648853523704832.00M
Annual income
$4,250,480,818,852,075,000,000,000.00/yr
Blended yield
98.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

NHIQ
No analyst data
Altman Z
-13.3
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NHIQ buys
0
MRK buys
0
No recent congressional trades found for NHIQ or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNHIQMRK
Forward yield16666.67%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$8601297707047409664.00M$56.8K
Annual income after 10y$8,500,961,637,704,150,000,000,000.00$9,798.13
Total dividends collected$8594666089931243520.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NHIQ vs MRK ($10,000, DRIP)

YearNHIQ PortfolioNHIQ Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,677,367$1,666,666.67$11,206$366.19+$1.67MNHIQ
2$263,066,849$261,272,066.46$12,650$502.35+$263.05MNHIQ
3$38,576,943,838$38,295,462,310.00$14,407$694.19+$38576.93MNHIQ
4$5,289,656,888,585$5,248,379,558,677.81$16,585$967.82+$5289656.87MNHIQ
5$678,235,585,150,030$672,575,652,279,244.40$19,342$1,363.89+$678235585.13MNHIQ
6$81,321,145,183,775,540$80,595,433,107,665,010.00$22,913$1,947.19+$81321145183.75MNHIQ
7$9,118,299,079,523,715,000$9,031,285,454,177,076,000.00$27,662$2,823.89+$9118299079523.69MNHIQ
8$956,159,646,381,740,000,000$946,403,066,366,649,700,000.00$34,159$4,173.35+$956159646381740.00MNHIQ
9$93,772,027,423,605,150,000,000$92,748,936,601,976,690,000,000.00$43,337$6,308.80+$93772027423605152.00MNHIQ
10$8,601,297,707,047,409,000,000,000$8,500,961,637,704,150,000,000,000.00$56,776$9,798.13+$8601297707047409664.00MNHIQ

NHIQ vs MRK: Complete Analysis 2026

NHIQStock

NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans, and centers for medicare and medicaid services for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers Quadris, a data solution that includes multi-data analysis, reporting, and professional services. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Morrisville, North Carolina. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.

Full NHIQ Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this NHIQ vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NHIQ vs SCHDNHIQ vs JEPINHIQ vs ONHIQ vs KONHIQ vs MAINNHIQ vs JNJNHIQ vs ABBVNHIQ vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.